<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Arthritis Res Ther</journal-id><journal-id journal-id-type="iso-abbrev">Arthritis Res. Ther</journal-id><journal-title-group><journal-title>Arthritis Research &#x00026; Therapy</journal-title></journal-title-group><issn pub-type="ppub">1478-6354</issn><issn pub-type="epub">1478-6362</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24507879</article-id><article-id pub-id-type="pmc">3979045</article-id><article-id pub-id-type="publisher-id">ar4479</article-id><article-id pub-id-type="doi">10.1186/ar4479</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Vitamin D levels in Indian systemic lupus erythematosus patients: association with disease activity index and interferon alpha</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="A1"><name><surname>Mandal</surname><given-names>Manamita</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>manamita51@gmail.com</email></contrib><contrib contrib-type="author" equal-contrib="yes" id="A2"><name><surname>Tripathy</surname><given-names>Rina</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>rinatripathy@hotmail.com</email></contrib><contrib contrib-type="author" id="A3"><name><surname>Panda</surname><given-names>Aditya K</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>adityarmrc@gmail.com</email></contrib><contrib contrib-type="author" id="A4"><name><surname>Pattanaik</surname><given-names>Sarit S</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>saritsekhar@gmail.com</email></contrib><contrib contrib-type="author" id="A5"><name><surname>Dakua</surname><given-names>Simanchal</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>drsdakua@gmail.com</email></contrib><contrib contrib-type="author" id="A6"><name><surname>Pradhan</surname><given-names>Anjan Kumar</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>pradhan.anjan@gmail.com</email></contrib><contrib contrib-type="author" id="A7"><name><surname>Chakraborty</surname><given-names>Soumen</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>soumen_ils@yahoo.co.in</email></contrib><contrib contrib-type="author" corresp="yes" id="A8"><name><surname>Ravindran</surname><given-names>Balachandran</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>ravindran8@gmail.com</email></contrib><contrib contrib-type="author" corresp="yes" id="A9"><name><surname>Das</surname><given-names>Bidyut K</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>bidyutdas@hotmail.com</email></contrib></contrib-group><aff id="I1"><label>1</label>Department of Medicine, SCB Medical College, Medical College Road, Cuttack, OD 753007, India</aff><aff id="I2"><label>2</label>Department of Biochemistry, SCB Medical College, Medical College Road, Cuttack, OD 753007, India</aff><aff id="I3"><label>3</label>Infectious Disease Biology Group, Institute of Life Sciences, Nalco Nagar Road, Bhubaneswar, OD 751023, India</aff><aff id="I4"><label>4</label>Department of Gene Function and Regulation, Institute of Life Sciences, Nalco Nagar Road, Bhubaneswar, OD 751023, India</aff><pub-date pub-type="ppub"><year>2014</year></pub-date><pub-date pub-type="epub"><day>10</day><month>2</month><year>2014</year></pub-date><volume>16</volume><issue>1</issue><fpage>R49</fpage><lpage>R49</lpage><history><date date-type="received"><day>12</day><month>5</month><year>2013</year></date><date date-type="accepted"><day>24</day><month>1</month><year>2014</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2014 Mandal et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>Mandal et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License (
<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://arthritis-research.com/content/16/1/R49"/><abstract><sec><title>Introduction</title><p>Low levels of vitamin D have been associated with several autoimmune disorders including multiple sclerosis, rheumatoid arthritis, type 1 diabetes and systemic lupus erythematosus (SLE). The major source of vitamin D is sunlight but exposure of SLE patients to UV rays has been shown to exacerbate disease pathology. Studies in various populations have shown an association between low vitamin D levels and higher SLE disease activity.</p></sec><sec><title>Methods</title><p>We enrolled 129 patients who fulfilled American College of Rheumatology criteria in the study. There were 79 treatment-na&#x000ef;ve cases and 50 patients who were under treatment for underlying SLE. There were 100 healthy subjects from similar geographical areas included as controls. Plasma 25-OH vitamin D<sub>3</sub> and interferon (IFN)-&#x003b1; levels were quantified by enzyme-linked immunosorbent assay (ELISA). The gene expression level of IFN-&#x003b1; was determined by quantitative real-time reverse transcriptase polymerase chain reaction (RT-PCR).</p></sec><sec><title>Results</title><p>Plasma 25-OH vitamin D<sub>3</sub> significantly correlated in an inverse manner with systemic lupus erythematosus disease activity index (SLEDAI) scores (<italic>P</italic> &#x0003c;0.0001, r&#x02009;=&#x02009;-0.42), anti-dsDNA (<italic>P</italic> &#x0003c;0.0001, r&#x02009;=&#x02009;-0.39), plasma IFN-&#x003b1; (<italic>P</italic> &#x0003c;0.0001, r&#x02009;=&#x02009;-0.43) and levels of IFN-&#x003b1; gene expression (<italic>P</italic>&#x02009;=&#x02009;0.0009, r&#x02009;=&#x02009;-0.45). Further, plasma levels of IFN-&#x003b1; positively correlated with gene expression of IFN-&#x003b1; (<italic>P</italic> &#x0003c;0.0001, r&#x02009;=&#x02009;0.84). Treatment-na&#x000ef;ve SLE patients displayed significantly higher plasma levels of IFN-&#x003b1; compared to patients under treatment (<italic>P</italic> &#x0003c;0.001) and controls (<italic>P</italic> &#x0003c;0.001).</p></sec><sec><title>Conclusions</title><p>These results suggest an important role of vitamin D in regulating disease activity in SLE patients and the need to supplement vitamin D in their treatment.</p></sec></abstract></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Systemic lupus erythematosus (SLE) is an autoimmune disorder which appears in a group of individuals and which is related to several factors, including environmental and host genetics that contribute to the development of the disease
[<xref ref-type="bibr" rid="B1">1</xref>]. Patients with SLE develop an immune response against numerous, mostly intracellular self-antigens. This results in formation of immune complexes that get deposited in vascular beds in most organs of the body. Immune complex deposition causes local inflammation and tissue damage that probably amplify the autoimmune response
[<xref ref-type="bibr" rid="B2">2</xref>]. This has serious consequences on the outcome of the disease.</p><p>The importance of vitamin D in various autoimmune disorders has been reported. Vitamin D deficiency has been associated with multiple sclerosis (MS), rheumatoid arthritis (RA), type 1 diabetes mellitus, inflammatory bowel disease (IBD), mixed connective tissue disease, autoimmune thyroid disease, scleroderma and SLE
[<xref ref-type="bibr" rid="B3">3</xref>-<xref ref-type="bibr" rid="B5">5</xref>]. Vitamin D supplementation improves disease outcome in various animal models of MS
[<xref ref-type="bibr" rid="B6">6</xref>], RA
[<xref ref-type="bibr" rid="B7">7</xref>], type 1 diabetes mellitus
[<xref ref-type="bibr" rid="B8">8</xref>], IBD
[<xref ref-type="bibr" rid="B9">9</xref>], autoimmune encephalomyelitis
[<xref ref-type="bibr" rid="B10">10</xref>] and SLE
[<xref ref-type="bibr" rid="B11">11</xref>]. The role of vitamin D in murine models of SLE has been investigated to a limited degree. Administration of vitamin D and its synthetic analogs to murine models has resulted in improved dermatological manifestations
[<xref ref-type="bibr" rid="B11">11</xref>], reduced proteinuria
[<xref ref-type="bibr" rid="B12">12</xref>] and increased survival
[<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B13">13</xref>]. An earlier report highlighted vitamin D<sub>3</sub> insufficiency in two-thirds, and deficiency (&#x0003c;10&#x000a0;ng/ml) in approximately one-fifth of SLE patients
[<xref ref-type="bibr" rid="B14">14</xref>]. In addition, serum vitamin D<sub>3</sub> (25-OH) levels have been found to correlate inversely with SLE disease activity index (SLEDAI) scores
[<xref ref-type="bibr" rid="B15">15</xref>-<xref ref-type="bibr" rid="B17">17</xref>].</p><p>The major source of vitamin D is the conversion of 7-dehydrocholesterol to previtamin D<sub>3</sub> in the skin when exposed to solar ultraviolet radiation
[<xref ref-type="bibr" rid="B18">18</xref>]. Previtamin D<sub>3</sub> then gets converted to vitamin D<sub>3</sub> (cholecalciferol) through a heat-mediated process in the skin
[<xref ref-type="bibr" rid="B18">18</xref>]. A lesser amount of vitamin D<sub>3</sub> (25-OH) is obtained from foods that supply less than 20% of the body&#x02019;s requirements. Vitamin D<sub>3</sub> undergoes two hydroxylations to achieve its functional form. The first hydroxylation occurs in the liver resulting in 25-hydroxyvitamin D (25(OH)D<sub>3</sub>) or calcidiol, which is normally quantified for evaluating vitamin D status, and the second hydroxylation takes place in the kidney to its active form 1,25-dihydroxyvitamin D3 (1, 25(OH)<sub>2</sub>D)
[<xref ref-type="bibr" rid="B18">18</xref>]. In addition to the liver and kidney, hydroxylation of vitamin D<sub>3</sub> also occurs in the lymph nodes and skin
[<xref ref-type="bibr" rid="B19">19</xref>].</p><p>Several studies worldwide have investigated the role of vitamin D<sub>3</sub> in the pathogenesis of SLE. However, to date, there have been no reports from an Indian population. Although the prevalence of SLE in India is rare (3 per 100,000)
[<xref ref-type="bibr" rid="B20">20</xref>], the survival rates of these patients (5-year: 70%; 10-year: 50%) are low compared to Western cohorts
[<xref ref-type="bibr" rid="B21">21</xref>,<xref ref-type="bibr" rid="B22">22</xref>]. Interestingly, vitamin D<sub>3</sub> insufficiency or deficiency appears to be widespread in the Indian subcontinent
[<xref ref-type="bibr" rid="B23">23</xref>], which makes it important to analyze its role in the background of SLE from an Indian cohort. We have addressed this issue in a tertiary-care, hospital-based, case-control study, to assess the role of vitamin D<sub>3</sub> in SLE in a cohort from eastern India.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Subjects</title><p>The patients recruited for the study were all inpatients, admitted to the Department of Medicine, under the Clinical Immunology and Rheumatology unit of SCB Medical College, Cuttack, Odisha. As described earlier
[<xref ref-type="bibr" rid="B24">24</xref>-<xref ref-type="bibr" rid="B26">26</xref>], diagnosis of SLE was based on the revised American College of Rheumatology (ACR) classification criteria
[<xref ref-type="bibr" rid="B27">27</xref>]. After a detailed clinical examination and laboratory investigation, the clinical manifestations were categorized. The clinical profiles of 129 SLE patients are summarized in Table&#x000a0;
<xref ref-type="table" rid="T1">1</xref>. Since, SLE affects women primarily
[<xref ref-type="bibr" rid="B28">28</xref>], 50 age-matched healthy females (medical students: HCA) and 50 healthy subjects from similar geographical areas (HCB) were included as healthy controls (HC). None of the controls reported any history of autoimmune disorder. About 5&#x000a0;ml blood in EDTA was collected from each participant. The study was approved by the institutional ethics committee of SCB Medical College, Cuttack. Informed consent was obtained from each patient and healthy control.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Clinical characteristics of SLE patients and healthy controls</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead valign="top"><tr><th align="left"><bold>Clinical profiles</bold></th><th align="left"><bold>SLE (n&#x02009;=&#x02009;129)</bold></th><th colspan="2" align="left"><bold>Healthy controls (n&#x02009;=&#x02009;100)</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="bottom"><bold>Sex (male/female)</bold><hr/></td><td align="left" valign="bottom">4/125<hr/></td><td colspan="2" align="left" valign="bottom">26/74<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Age in years (mean&#x02009;&#x000b1;&#x02009;SD)</bold><hr/></td><td align="left" valign="bottom">28.14&#x02009;&#x000b1;&#x02009;8.43<hr/></td><td colspan="2" align="left" valign="bottom">31.18&#x02009;&#x000b1;&#x02009;5.32<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Duration of disease years (mean&#x02009;&#x000b1;&#x02009;SD)</bold><hr/></td><td align="left" valign="bottom">2.90&#x02009;&#x000b1;&#x02009;2.66<hr/></td><td colspan="2" align="left" valign="bottom">-<hr/></td></tr><tr><td align="left" valign="bottom"><bold>SLEDAI scores (mean&#x02009;&#x000b1;&#x02009;SD)</bold><hr/></td><td align="left" valign="bottom">18.36&#x02009;&#x000b1;&#x02009;6.73<hr/></td><td colspan="2" align="left" valign="bottom">-<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Photosensitivity rash</bold><hr/></td><td align="left" valign="bottom">34 (26)<hr/></td><td colspan="2" align="left" valign="bottom">-<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Malar rash</bold><hr/></td><td align="left" valign="bottom">73 (57)<hr/></td><td colspan="2" align="left" valign="bottom">-<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Discoid rash</bold><hr/></td><td align="left" valign="bottom">14 (11)<hr/></td><td colspan="2" align="left" valign="bottom">-<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Oral ulcer</bold><hr/></td><td align="left" valign="bottom">76 (59)<hr/></td><td colspan="2" align="left" valign="bottom">-<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Arthritis</bold><hr/></td><td align="left" valign="bottom">77 (60)<hr/></td><td colspan="2" align="left" valign="bottom">-<hr/></td></tr><tr><td align="left" valign="bottom"><bold>NPSLE</bold><hr/></td><td align="left" valign="bottom">11 (9)<hr/></td><td colspan="2" align="left" valign="bottom">-<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Myocarditis</bold><hr/></td><td align="left" valign="bottom">3 (2)<hr/></td><td colspan="2" align="left" valign="bottom">-<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Serositis</bold><hr/></td><td align="left" valign="bottom">7 (5)<hr/></td><td colspan="2" align="left" valign="bottom">-<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Nephritis</bold><hr/></td><td align="left" valign="bottom">46 (37)<hr/></td><td colspan="2" align="left" valign="bottom">-<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Vasculitis</bold><hr/></td><td align="left" valign="bottom">17 (13)<hr/></td><td colspan="2" align="left" valign="bottom">-<hr/></td></tr><tr><td colspan="2" align="left" valign="bottom"><bold>Treatment details of patients under therapy at the time of recruitment to the study (n&#x02009;=&#x02009;50)</bold><hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">Medicine<hr/></td><td align="left" valign="bottom">Quantity<hr/></td><td align="left" valign="bottom">Number of patient treated (%)<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">Prednisolone; mean (range)<hr/></td><td align="left" valign="bottom">18.99&#x000a0;mg (5-50&#x000a0;mg)<hr/></td><td align="left" valign="bottom">50 (100)<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">Hydroxychloroquine<hr/></td><td align="left" valign="bottom">6.5&#x000a0;mg/kg body weight<hr/></td><td align="left" valign="bottom">50 (100)<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">Calcium<hr/></td><td align="left" valign="bottom">1&#x000a0;g/day<hr/></td><td align="left" valign="bottom">50 (100)<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">Vitamin D<sub>3</sub><hr/></td><td align="left" valign="bottom">250-500&#x000a0;IU/day<hr/></td><td align="left" valign="bottom">50 (100)<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">Azathioprine<hr/></td><td align="left" valign="bottom">50-100&#x000a0;mg/day<hr/></td><td align="left" valign="bottom">4 (8)<hr/></td></tr><tr><td align="left">&#x000a0;</td><td align="left">Mycophenolate mofetil</td><td align="left">2 gm/day</td><td align="left">4 (8)</td></tr></tbody></table><table-wrap-foot><p>Note: data are number (%) of participants unless otherwise specified. SLE, systemic lupus erythematosus; SLEDAI, SLE disease activity index; NPSLE<italic>,</italic> neuropsychiatric systemic lupus erythematosus.</p></table-wrap-foot></table-wrap></sec><sec><title>25-OH vitamin D quantification in plasma</title><p>The plasma levels of 25-OH Vitamin D were quantified by enzyme-linked immunosorbent assay (ELISA) kit (CPC, Euroimmun, L&#x000fc;beck, Germany) according to the manufacturer&#x02019;s instructions. Vitamin D deficiency was defined as plasma levels of 25-OH vitamin D &#x0003c;10&#x000a0;ng/ml and insufficiency as 10 to 30&#x000a0;ng/ml
[<xref ref-type="bibr" rid="B18">18</xref>].</p></sec><sec><title>Quantification of plasma interferon alpha</title><p>Plasma levels of interferon (IFN)-&#x003b1; were measured by ELISA kit (Bender MedSystems Inc., Burlingame, CA, USA) according to the manufacturer&#x02019;s protocol.</p></sec><sec><title>RNA extraction and reverse transcription</title><p>According to the manufacturer&#x02019;s instructions, total RNA was isolated from 250&#x000a0;&#x003bc;l of whole blood by TRIzol LS reagent (Invitrogen, Carlsbad, CA, USA). RNA concentration was determined by spectrophotometry using an Implen NanoPhotometer (Implen, Munich, Germany). To remove any traces of genomic DNA, 1&#x000a0;&#x003bc;g of total RNA was then treated with 2U DNase (Sigma-Aldrich, St Louis, MO, USA) for 30&#x000a0;min at 37&#x000b0;C. DNase-treated RNA was reverse transcribed with a hexamer primer using a First Strand cDNA Synthesis kit (Thermo Fisher Scientific, Waltham, MA, USA), according to the manufacturer&#x02019;s instructions. Once the cDNA was synthesized, its fidelity was tested by PCR and stored at -70&#x000b0;C.</p></sec><sec><title>Real-time PCR assay</title><p>Real-time PCR assay of IFN-&#x003b1; was carried out as described earlier
[<xref ref-type="bibr" rid="B29">29</xref>]. Briefly, reactions were set up in a total volume of 20&#x000a0;&#x003bc;l using 2&#x000a0;&#x003bc;l of cDNA, 10&#x000a0;&#x003bc;l of MESA GREEN qPCR MasterMix Plus (Eurogentec, Seraing, Belgium) and 10 picomole each of gene-specific primer (IFN-&#x003b1; (sense: 5&#x02032;-TTCCTCCTGYYTGAWGGACAGA-3; antisense: 5&#x02032;-GATCTCATGATTTCTGCTCTGACA-3&#x02032;), glyceraldehyde-3 phosphate dehydrogenase (G3PDH) was taken as control (sense: 5&#x02032;-GGTATCGTGGAAGGACTCATGAC-3&#x02032;; antisense: 5&#x02032;-ATGCCAGTGAGCTTCCCGTTCAGC-3&#x02032;)) and performed in the MJ Research DNA Engine Opticon Real-Time Thermal Cycler (MJ Research, Waltham, MA, USA).The cycling conditions were: 95&#x000b0;C for 4&#x000a0;min; 35&#x000a0;cycles of 95&#x000b0;C for 30&#x000a0;s, 55&#x000b0;C for 30&#x000a0;s and 72&#x000b0;C for 30&#x000a0;s with a single fluorescence measurement; a final elongation step was carried out at 72&#x000b0;C for 10&#x000a0;min. Specificity of the PCR products was confirmed by analysis of the dissociation curve. The melting curve program consisted of temperatures between 55 and 95&#x000b0;C with a heating rate of 0.1&#x000b0;C/s and a continuous fluorescence measurement. Additionally, the amplicons&#x02019; expected size and the absence of nonspecific products were confirmed by analysis of the real-time PCR products in 1% agarose gel in 1&#x02009;&#x000d7;&#x02009;TBE, stained with ethidium bromide and visualized under ultraviolet light (expected product size of IFN-&#x003b1;: 375&#x000a0;bp and G3PDH: 187&#x000a0;bp). IFN-&#x003b1; gene expression in each sample was calculated by the 2<sup>-&#x00394;Ct</sup> method (&#x00394;Ct&#x02009;=&#x02009;Ct of IFN-&#x003b1; &#x02013; Ct of GAPDH)
[<xref ref-type="bibr" rid="B30">30</xref>].</p></sec><sec><title>Statistical analysis</title><p>All statistical analysis was performed by GraphPad prism 5.01 (GraphPad Software, San Diego, CA, USA). Distribution of plasma 25-OH vitamin D<sub>3</sub> and IFN-&#x003b1; in treatment-na&#x000ef;ve SLE patients, controls and treated patients were assessed by D&#x02019;Agostino-Pearson omnibus normality test. Based on the results of the normality test, the association of 25-OH vitamin D<sub>3</sub> and IFN-&#x003b1; with clinical disease was analyzed by analysis of variance (ANOVA) or Kruskal-Wallis test followed by an appropriate post test. Correlation of 25-OH vitamin D<sub>3</sub> with double-stranded (ds)DNA, SLEDAI scores and IFN-&#x003b1; was analyzed by Spearman&#x02019;s correlation test. Further correlation of IFN-&#x003b1; gene expression with plasma IFN-&#x003b1; and 25-OH vitamin D<sub>3</sub> levels was analyzed by Spearman&#x02019;s correlation test. A <italic>P</italic> value &#x0003c;0.05 was considered as significant.</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>Clinical characteristics of SLE patients</title><p>One hundred and twenty-nine patients were enrolled in the current study. Baseline characteristics are shown in Table&#x000a0;
<xref ref-type="table" rid="T1">1</xref>. There were 125 (97%) females and 4 (3%) males with a mean age (standard deviation) of 28.14 (8.43) years. The mean duration of disease (standard deviation) was 2.90&#x000a0;years (2.66). Out of the 129 SLE patients, 50 patients included in the study were already on treatment for SLE and were also receiving supplements of oral calcium and vitamin D<sub>3</sub> at the time of blood collection (Table&#x000a0;
<xref ref-type="table" rid="T1">1</xref>). The other 79 patients were treatment-naive cases, undiagnosed earlier and the details of the treatment received for their complaints before hospitalization were not known since the patients had not maintained any records. The clinical profiles of patients were as follows: photosensitivity rash (26%), malar rash (57%), discoid rash (11%), oral ulcer (59%), arthritis (60%), neuropsychiatric disease (9%), myocarditis (2%), serositis (5%), nephritis (37%) and vasculitis (13%) (Table&#x000a0;
<xref ref-type="table" rid="T1">1</xref>).</p></sec><sec><title>Plasma 25-OH vitamin D<sub>3</sub> levels in SLE patients and healthy controls</title><p>Plasma levels of 25-OH vitamin D<sub>3</sub> in SLE patients and healthy controls were quantified by ELISA and the results are shown in Figure&#x000a0;
<xref ref-type="fig" rid="F1">1</xref>. Patients under vitamin D<sub>3</sub> supplementation (treated cases) displayed significantly higher levels of 25-OH vitamin D<sub>3</sub> compared to treatment-na&#x000ef;ve patients (<italic>P</italic> &#x0003c;0.001) and healthy controls (<italic>P</italic> &#x0003c;0.001). The levels of plasma 25-OH vitamin D<sub>3</sub> in treatment-na&#x000ef;ve SLE patients and healthy controls were comparable.</p><fig id="F1" position="float"><label>Figure 1</label><caption><p><bold>25-OH vitamin D</bold><sub><bold>3 </bold></sub><bold>levels in SLE patients and healthy controls.</bold> Plasma samples from SLE patients (treatment-na&#x000ef;ve case (n&#x02009;=&#x02009;79); treated patients (n&#x02009;=&#x02009;50)) and healthy controls (HCA: medical students (n&#x02009;=&#x02009;50); HCB: controls from same locality (n&#x02009;=&#x02009;50)) were quantified by ELISA according to the manufacturer&#x02019;s instructions. Treated SLE patients displayed significantly higher concentrations of plasma 25-OH vitamin D<sub>3</sub> levels compared to treatment-na&#x000ef;ve patients (<italic>P</italic> &#x0003c;0.001) and controls (HCA: (<italic>P</italic> &#x0003c;0.001); HCB: (<italic>P</italic> &#x0003c;0.01)). SLE, systemic lupus erythematosus.</p></caption><graphic xlink:href="ar4479-1"/></fig></sec><sec><title>Vitamin D<sub>3</sub> levels negatively correlated with SLEDAI scores and anti-dsDNA</title><p>Analysis of data in SLE patients revealed a significant negative correlation between plasma 25-OH vitamin D<sub>3</sub> levels with SLEDAI scores (<italic>P</italic> &#x0003c;0.0001, r&#x02009;=&#x02009;-0.42) (Figure&#x000a0;
<xref ref-type="fig" rid="F2">2</xref>A) and anti-dsDNA (<italic>P</italic> &#x0003c;0.0001, r&#x02009;=&#x02009;-0.39) (Figure&#x000a0;
<xref ref-type="fig" rid="F2">2</xref>B). Further, SLE patients were categorized into two groups: treatment-na&#x000ef;ve and those under treatment. As shown in Figure&#x000a0;
<xref ref-type="fig" rid="F2">2</xref>C and D, irrespective of treatment status, the plasma levels of 25-OH vitamin D<sub>3</sub> negatively correlated with SLEDAI scores. In addition, a further analysis of the relationship between 25-OH vitamin D<sub>3</sub> and modified SLEDAI scores (eliminating the anti-dsDNA positive score of 2 from SLEDAI), revealed identical results in both the groups (Figures&#x000a0;
<xref ref-type="fig" rid="F2">2</xref>E and F). These findings indicate a significant association between 25-OH vitamin D<sub>3</sub> and disease activity in SLE.</p><fig id="F2" position="float"><label>Figure 2</label><caption><p><bold>Correlation of 25-OH vitamin D</bold><sub><bold>3 </bold></sub><bold>with SLEDAI scores and anti-dsDNA levels.</bold> Plasma 25-OH vitamin D<sub>3</sub> levels of SLE patients correlated negatively with SLEDAI scores <bold>(A)</bold> and anti-dsDNA <bold>(B)</bold>. SLE patients were categorized into two groups: treatment-na&#x000ef;ve cases and patients under treatment. In both groups plasma levels of 25-OH vitamin D<sub>3</sub> negatively correlated with SLEDAI scores <bold>(C</bold> and <bold>D)</bold>. Modified SLEDAI scores (eliminating the anti-dsDNA score of 2) and its correlation with plasma levels of 25-OH vitamin D<sub>3</sub> were analyzed. Similar to earlier observations, SLEDAI scores (-anti-dsDNA) negatively correlated with 25-OH vitamin D<sub>3</sub> levels in both treatment-na&#x000ef;ve cases <bold>(E)</bold> and treated patients <bold>(F)</bold>. Dots represent individual samples. Correlation analysis was performed by Spearman&#x02019;s correlation coefficient. A <italic>P</italic> value less than 0.05 was considered as significant. SLEDAI, systemic lupus erythematosus disease activity index; SLE, systemic lupus erythematosus; dsDNA, double-stranded DNA.</p></caption><graphic xlink:href="ar4479-2"/></fig></sec><sec><title>Correlation between 25-OH vitamin D<sub>3</sub> and IFN-&#x003b1;</title><p>The role of IFN-&#x003b1; in SLE has been clearly documented and its significant correlation with SLEDAI scores has been demonstrated in patients from different populations
[<xref ref-type="bibr" rid="B31">31</xref>,<xref ref-type="bibr" rid="B32">32</xref>]. As shown in Figure&#x000a0;
<xref ref-type="fig" rid="F3">3</xref>A, a significant negative correlation was observed between 25-OH vitamin D<sub>3</sub> levels and plasma IFN-&#x003b1; (<italic>P</italic> &#x0003c;0.0001, r&#x02009;=&#x02009;-0.43). Treatment-na&#x000ef;ve patients displayed higher levels of plasma IFN-&#x003b1; compared to SLE patients on treatment (<italic>P</italic> &#x0003c;0.001) and healthy controls (<italic>P</italic> &#x0003c;0.001) (Figure&#x000a0;
<xref ref-type="fig" rid="F3">3</xref>B) suggesting an important role of IFN-&#x003b1; in modulating disease activity.</p><fig id="F3" position="float"><label>Figure 3</label><caption><p><bold>Correlation of plasma IFN-&#x003b1; with 25-OH vitamin D</bold><sub><bold>3 </bold></sub><bold>and its levels in SLE patients and controls. (A)</bold> Plasma 25-OH vitamin D<sub>3</sub> levels correlated negatively with IFN-&#x003b1; levels. Dots represent individual samples. Correlation analysis was performed by Spearman&#x02019;s correlation coefficient. <bold>(B)</bold> Treatment-na&#x000ef;ve patients displayed significantly higher levels of IFN-&#x003b1; compared to treated cases and healthy controls. Mean plasma levels of IFN-&#x003b1; in different clinical categories were compared by ANOVA followed by Tukey&#x02019;s multiple comparisons test. A <italic>P</italic> value less than 0.05 was considered as significant. IFN-&#x003b1;, interferon alpha; SLE, systemic lupus erythematosus.</p></caption><graphic xlink:href="ar4479-3"/></fig></sec><sec><title>Correlation of IFN-&#x003b1; gene expression with plasma IFN-&#x003b1; and 25-OH vitamin D<sub>3</sub> levels</title><p>To validate the robustness of IFN-&#x003b1; data, considering that it is an evanescent cytokine, we quantified IFN-&#x003b1; gene expression by RT-PCR in SLE patients (n&#x02009;=&#x02009;49) and correlated the values with plasma levels of IFN-&#x003b1; and 25-OH vitamin D<sub>3</sub>. As shown in Figure&#x000a0;
<xref ref-type="fig" rid="F4">4</xref>A, a strong positive correlation was observed between IFN-&#x003b1; plasma levels and its gene expression (<italic>P</italic> &#x0003c;0.0001, r&#x02009;=&#x02009;84). In addition, IFN-&#x003b1; gene expression negatively correlated with plasma 25-OH vitamin D<sub>3</sub> (<italic>P</italic>&#x02009;=&#x02009;0.0009, r&#x02009;=&#x02009;-45) (Figure&#x000a0;
<xref ref-type="fig" rid="F4">4</xref>B).</p><fig id="F4" position="float"><label>Figure 4</label><caption><p><bold>Correlation of IFN-&#x003b1; gene expression with plasma IFN-&#x003b1; levels and 25-OH vitamin D</bold><sub><bold>3</bold></sub><bold>.</bold> Plasma levels of IFN-&#x003b1; and gene expression levels were quantified by ELISA and RT-PCR respectively. <bold>(A)</bold> Plasma levels of IFN-&#x003b1; positively correlated with gene expression (2 <sup>&#x02013; &#x00394;ct</sup>) of IFN-&#x003b1;. <bold>(B)</bold> IFN-&#x003b1; gene expression (2 <sup>&#x02013; &#x00394;ct</sup>) correlated negatively with plasma levels of 25-OH vitamin D<sub>3</sub>. Dots represent individual samples. Correlation analysis was performed by Spearman&#x02019;s correlation coefficient. A <italic>P</italic> value less than 0.05 was considered as significant. IFN-&#x003b1;, interferon alpha.</p></caption><graphic xlink:href="ar4479-4"/></fig></sec><sec><title>Association of plasma IFN-&#x003b1; with SLE disease severity</title><p>Role of IFN-&#x003b1; in the pathogenesis of SLE is an important issue that is being investigated
[<xref ref-type="bibr" rid="B32">32</xref>]. We analyzed the association of IFN-&#x003b1; with disease severity. As shown in Figure&#x000a0;
<xref ref-type="fig" rid="F5">5</xref>A, plasma levels of IFN-&#x003b1; positively correlated with SLEDAI scores (r&#x02009;=&#x02009;0.26, <italic>P</italic>&#x02009;=&#x02009;0.002) and patients with severe phenotype displayed significantly higher levels of IFN-&#x003b1; compared to those with mild disease manifestations (<italic>P</italic>&#x02009;=&#x02009;0.01) (Figure&#x000a0;
<xref ref-type="fig" rid="F5">5</xref>B). However, duration of disease did not correlate with plasma IFN-&#x003b1; levels (data not shown). We also observed a significant inverse correlation between plasma 25-OH vitamin D<sub>3</sub> and IFN-&#x003b1; levels. This correlation held true while analyzing the association between 25-OH vitamin D<sub>3</sub> levels and IFN-&#x003b1; gene expression.</p><fig id="F5" position="float"><label>Figure 5</label><caption><p><bold>Correlation of plasma IFN-&#x003b1; with SLEDAI scores and association with organ involvement. (A)</bold> Plasma levels of IFN-&#x003b1; positively correlated with SLEDAI scores. Dots represent individual samples. Correlation analysis was performed by Spearman&#x02019;s correlation coefficient. A <italic>P</italic> value less than 0.05 was considered as significant. <bold>(B)</bold> Based on clinical phenotype SLE patients were categorized into two broad groups and plasma levels of IFN-&#x003b1; were compared. Patients with major disease manifestation displayed significantly higher plasma levels of IFN-&#x003b1; than those with minor disease manifestation. Mean plasma levels of IFN-&#x003b1; were compared by unpaired <italic>t</italic> test and a <italic>P</italic> value less than 0.05 was taken as significant. IFN-&#x003b1;, interferon alpha; SLEDAI, systemic lupus erythematosus disease activity index; SLE, systemic lupus erythematosus.</p></caption><graphic xlink:href="ar4479-5"/></fig></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>The role of vitamin D<sub>3</sub> in autoimmune disorders has been the subject of several studies with regard to its importance as an immune regulator
[<xref ref-type="bibr" rid="B33">33</xref>]. This is the first study from India to demonstrate an association between vitamin D<sub>3</sub> and SLE, highlighting its significant inverse correlation with SLEDAI scores, anti-dsDNA and IFN-&#x003b1;. These are markers of disease activity and IFN-&#x003b1; is closely associated with disease pathogenesis.</p><p>Low levels of vitamin D<sub>3</sub> in SLE patients have been reported compared to healthy controls in different populations
[<xref ref-type="bibr" rid="B34">34</xref>]. Interestingly, mean plasma levels of 25-OH vitamin D3 were not significantly different among treatment-na&#x000ef;ve SLE cases (11.61&#x000a0;ng/ml), healthy medical students (9.55&#x000a0;ng/ml) and other healthy controls from same locality (13.36&#x000a0;ng/ml). Vitamin D<sub>3</sub> insufficiency has been reported to be widely prevalent in the Indian subcontinent irrespective of the social class
[<xref ref-type="bibr" rid="B23">23</xref>]. Two groups of healthy controls were analyzed, which included medical students (HCA), who led a lifestyle marked by poor exposure to sunlight and irregular dietary habits, and a group of healthy subjects from the same locality (HCB). Interestingly, 63% of healthy medical students were deficient and 37% were insufficient of vitamin D<sub>3</sub>. Furthermore, 94% of the other groups of healthy controls were either deficient or insufficient of vitamin D<sub>3</sub>. This was an important observation considering India being a tropical country with lots of sunshine. However, the facts were contrary and several hypotheses have been discussed to explain the discrepancy. Higher melanin concentration in the skin
[<xref ref-type="bibr" rid="B35">35</xref>], current lifestyle changes, avoidance of sunlight and poor food habits are some of the causes attributed to the widespread prevalence of low vitamin D<sub>3</sub> among Indians. Low vitamin D<sub>3</sub> may not be cause for development of SLE but persons with low serum levels are likely to suffer from severe disease. The current cross-sectional study does not address the issue of cause and effect relationship between vitamin D<sub>3</sub> and SLE.</p><p>There are several interesting observations in the current study that points to an important role for vitamin D<sub>3</sub> in disease modulation. One of them being a significant inverse correlation between vitamin D<sub>3</sub> and SLEDAI scores and the other association is between vitamin D<sub>3</sub> and anti-dsDNA. Association between plasma vitamin D<sub>3</sub> and SLEDAI scores has not been uniform across observations: several studies have reported a negative correlation
[<xref ref-type="bibr" rid="B15">15</xref>-<xref ref-type="bibr" rid="B17">17</xref>], while others have found none
[<xref ref-type="bibr" rid="B36">36</xref>-<xref ref-type="bibr" rid="B39">39</xref>].</p><p>One of the important functions of vitamin D<sub>3</sub> is maintenance of homeostasis of B cells
[<xref ref-type="bibr" rid="B40">40</xref>]. Low levels of vitamin D<sub>3</sub> contribute to hyperactivity of B cells and enhanced production of autoantibodies
[<xref ref-type="bibr" rid="B41">41</xref>]. Furthermore, vitamin D<sub>3</sub> is known to modulate various immunological pathways
[<xref ref-type="bibr" rid="B33">33</xref>] and thus could have a defining role in the development, progression and pathogenesis of SLE. Vitamin D<sub>3</sub> also inhibits differentiation of dendritic cells (DCs) and T-helper cells (CD4+)
[<xref ref-type="bibr" rid="B42">42</xref>], enhances T regulatory cell proliferation and suppresses release of inflammatory mediators
[<xref ref-type="bibr" rid="B43">43</xref>], which collectively help in control of autoimmune disorders.</p><p>In recent years, the role of interferon in the pathogenesis of lupus has been widely investigated. Higher levels of IFN-&#x003b1; were observed in our SLE patients compared to healthy controls, corroborating earlier observations
[<xref ref-type="bibr" rid="B32">32</xref>,<xref ref-type="bibr" rid="B44">44</xref>-<xref ref-type="bibr" rid="B46">46</xref>]. The interferon levels were significantly low in patients under treatment compared to treatment-na&#x000ef;ve cases, supporting its possible role in disease modulation. Furthermore, IFN-&#x003b1; could be a marker of disease activity and low levels in treated patients could indicate response to therapy.</p><p>Interestingly, our study revealed a strong negative correlation of vitamin D<sub>3</sub> with IFN-&#x003b1; (<italic>P</italic> &#x0003c;0.0001, r&#x02009;=&#x02009;-0.52). The robustness of the assay was validated by assessment of IFN-&#x003b1; gene expression, which corroborated with the earlier observations on the association between plasma IFN-&#x003b1; and vitamin D<sub>3</sub>. There are no reports in the literature assessing the association between IFN-&#x003b1; and vitamin D<sub>3</sub>.</p><p>In active SLE overexpression of interferon-inducible genes (IFN signature) has been reported
[<xref ref-type="bibr" rid="B47">47</xref>]. The major source of IFN-&#x003b1; in SLE patients are activated DCs. Maturation/activation of DCs and production of IFN-&#x003b1; has been observed to be inhibited by vitamin D in <italic>in vitro</italic> studies
[<xref ref-type="bibr" rid="B48">48</xref>,<xref ref-type="bibr" rid="B49">49</xref>]. A direct role for vitamin D<sub>3</sub> in modulating lupus activity has been demonstrated in animal models
[<xref ref-type="bibr" rid="B11">11</xref>-<xref ref-type="bibr" rid="B13">13</xref>]. Our observations, although cross-sectional, and studies on experimental models, provide evidence for a disease-modulating role for vitamin D<sub>3</sub>, which could be a promising therapeutic adjunct in the treatment of SLE. In view of the limited number of drugs available for the treatment of lupus and the low cost of vitamin D<sub>3</sub> therapy, there is a strong case for its use routinely.</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>To conclude, vitamin D deficiency is prevalent among healthy Indians as well as among SLE patients. The significant inverse correlation of vitamin D<sub>3</sub> with SLEDAI scores, anti-dsDNA and IFN-&#x003b1; highlights its immune-modulatory role contributing to disease outcome. Although the present study indicates a necessity for vitamin D<sub>3</sub> supplementation in the management of SLE patients, larger randomized controlled trials would be necessary to define the daily requirement and optimum blood levels of vitamin D<sub>3</sub> that are effective in influencing disease outcome.</p></sec><sec><title>Abbreviations</title><p>ACR: American College of Rheumatology; C3: complement component 3; C4: complement component 4; DCs: dendritic cells; dsDNA: double-stranded DNA; ELISA: enzyme-linked immunosorbent assay; HC: healthy controls; IBD: inflammatory bowel disease; IFN-&#x003b1;: interferon alpha; MS: multiple sclerosis; NPSLE: neuropsychiatric systemic lupus erythematosus; RT-PCR: real-time polymerase chain reaction; RA: rheumatoid arthritis; SLE: systemic lupus erythematosus; SLEDAI: systemic lupus erythematosus disease activity index.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors&#x02019; contributions</title><p>MM, SD and SSP were involved in samples collection, data management and clinical categorization of samples. AdKP carried out quantification of IFN-&#x003b1; by ELISA, real-time PCR, data interpretation and wrote the first draft of the manuscript. AnKP and SC quantified IFN-&#x003b1; gene expression and interpreted the results. RT performed all routine tests including measurement of vitamin D. RT, BR and BKD made a contribution in the design, data interpretation, work supervision and critically revising the manuscript. All authors read and approved the manuscript.</p></sec></body><back><sec><title>Acknowledgements</title><p>The work was partly supported by intramural grants from the Department of Biotechnology, Government of India to the Institute of Life Sciences, Bhubaneswar. We would like to thank all patients and controls included in this study. We also thank to Mr. Subrat K. Mohanty for collection of blood from patients and healthy controls.</p></sec><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Crispin</surname><given-names>JC</given-names></name><name><surname>Liossis</surname><given-names>SN</given-names></name><name><surname>Kis-Toth</surname><given-names>K</given-names></name><name><surname>Lieberman</surname><given-names>LA</given-names></name><name><surname>Kyttaris</surname><given-names>VC</given-names></name><name><surname>Juang</surname><given-names>YT</given-names></name><name><surname>Tsokos</surname><given-names>GC</given-names></name><article-title>Pathogenesis of human systemic lupus erythematosus: recent advances</article-title><source>Trends Mol Med</source><year>2010</year><volume>16</volume><fpage>47</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1016/j.molmed.2009.12.005</pub-id><pub-id pub-id-type="pmid">20138006</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Tsokos</surname><given-names>GC</given-names></name><article-title>Systemic lupus erythematosus</article-title><source>N Engl J Med</source><year>2011</year><volume>16</volume><fpage>2110</fpage><lpage>2121</lpage><pub-id pub-id-type="doi">10.1056/NEJMra1100359</pub-id><pub-id pub-id-type="pmid">22129255</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Gatenby</surname><given-names>P</given-names></name><name><surname>Lucas</surname><given-names>R</given-names></name><name><surname>Swaminathan</surname><given-names>A</given-names></name><article-title>Vitamin D deficiency and risk for rheumatic diseases: an update</article-title><source>Curr Opin Rheumatol</source><year>2013</year><volume>16</volume><fpage>184</fpage><lpage>191</lpage><pub-id pub-id-type="doi">10.1097/BOR.0b013e32835cfc16</pub-id><pub-id pub-id-type="pmid">23370372</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Pludowski</surname><given-names>P</given-names></name><name><surname>Holick</surname><given-names>MF</given-names></name><name><surname>Pilz</surname><given-names>S</given-names></name><name><surname>Wagner</surname><given-names>CL</given-names></name><name><surname>Hollis</surname><given-names>BW</given-names></name><name><surname>Grant</surname><given-names>WB</given-names></name><name><surname>Shoenfeld</surname><given-names>Y</given-names></name><name><surname>Lerchbaum</surname><given-names>E</given-names></name><name><surname>Llewellyn</surname><given-names>DJ</given-names></name><name><surname>Kienreich</surname><given-names>K</given-names></name><name><surname>Soni</surname><given-names>M</given-names></name><article-title>Vitamin D effects on musculoskeletal health, immunity, autoimmunity, cardiovascular disease, cancer, fertility, pregnancy, dementia and mortality-a review of recent evidence</article-title><source>Autoimmun Rev</source><year>2013</year><volume>16</volume><fpage>976</fpage><lpage>989</lpage><pub-id pub-id-type="doi">10.1016/j.autrev.2013.02.004</pub-id><pub-id pub-id-type="pmid">23542507</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>Yang</surname><given-names>CY</given-names></name><name><surname>Leung</surname><given-names>PS</given-names></name><name><surname>Adamopoulos</surname><given-names>IE</given-names></name><name><surname>Gershwin</surname><given-names>ME</given-names></name><article-title>The implication of vitamin D and autoimmunity: a comprehensive review</article-title><source>Clin Rev Allergy Immunol</source><year>2013</year><volume>16</volume><fpage>217</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.1007/s12016-013-8361-3</pub-id><pub-id pub-id-type="pmid">23359064</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>Munger</surname><given-names>KL</given-names></name><name><surname>Levin</surname><given-names>LI</given-names></name><name><surname>Hollis</surname><given-names>BW</given-names></name><name><surname>Howard</surname><given-names>NS</given-names></name><name><surname>Ascherio</surname><given-names>A</given-names></name><article-title>Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis</article-title><source>JAMA</source><year>2006</year><volume>16</volume><fpage>2832</fpage><lpage>2838</lpage><pub-id pub-id-type="doi">10.1001/jama.296.23.2832</pub-id><pub-id pub-id-type="pmid">17179460</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name><surname>Cantorna</surname><given-names>MT</given-names></name><name><surname>Hayes</surname><given-names>CE</given-names></name><name><surname>DeLuca</surname><given-names>HF</given-names></name><article-title>1,25-Dihydroxycholecalciferol inhibits the progression of arthritis in murine models of human arthritis</article-title><source>J Nutr</source><year>1998</year><volume>16</volume><fpage>68</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">9430604</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><name><surname>Mathieu</surname><given-names>C</given-names></name><name><surname>Waer</surname><given-names>M</given-names></name><name><surname>Laureys</surname><given-names>J</given-names></name><name><surname>Rutgeerts</surname><given-names>O</given-names></name><name><surname>Bouillon</surname><given-names>R</given-names></name><article-title>Prevention of autoimmune diabetes in NOD mice by 1,25 dihydroxyvitamin D3</article-title><source>Diabetologia</source><year>1994</year><volume>16</volume><fpage>552</fpage><lpage>558</lpage><pub-id pub-id-type="doi">10.1007/BF00403372</pub-id><pub-id pub-id-type="pmid">7926338</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><name><surname>Cantorna</surname><given-names>MT</given-names></name><name><surname>Munsick</surname><given-names>C</given-names></name><name><surname>Bemiss</surname><given-names>C</given-names></name><name><surname>Mahon</surname><given-names>BD</given-names></name><article-title>1,25-Dihydroxycholecalciferol prevents and ameliorates symptoms of experimental murine inflammatory bowel disease</article-title><source>J Nutr</source><year>2000</year><volume>16</volume><fpage>2648</fpage><lpage>2652</lpage><pub-id pub-id-type="pmid">11053501</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><name><surname>Lemire</surname><given-names>JM</given-names></name><name><surname>Archer</surname><given-names>DC</given-names></name><article-title>1,25-dihydroxyvitamin D3 prevents the in vivo induction of murine experimental autoimmune encephalomyelitis</article-title><source>J Clin Invest</source><year>1991</year><volume>16</volume><fpage>1103</fpage><lpage>1107</lpage><pub-id pub-id-type="doi">10.1172/JCI115072</pub-id><pub-id pub-id-type="pmid">1705564</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><name><surname>Lemire</surname><given-names>JM</given-names></name><name><surname>Ince</surname><given-names>A</given-names></name><name><surname>Takashima</surname><given-names>M</given-names></name><article-title>1,25-Dihydroxyvitamin D3 attenuates the expression of experimental murine lupus of MRL/l mice</article-title><source>Autoimmunity</source><year>1992</year><volume>16</volume><fpage>143</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.3109/08916939209150321</pub-id><pub-id pub-id-type="pmid">1617111</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><name><surname>Abe</surname><given-names>J</given-names></name><name><surname>Nakamura</surname><given-names>K</given-names></name><name><surname>Takita</surname><given-names>Y</given-names></name><name><surname>Nakano</surname><given-names>T</given-names></name><name><surname>Irie</surname><given-names>H</given-names></name><name><surname>Nishii</surname><given-names>Y</given-names></name><article-title>Prevention of immunological disorders in MRL/l mice by a new synthetic analogue of vitamin D3: 22-oxa-1 alpha,25-dihydroxyvitamin D3</article-title><source>J Nutr Sci Vitaminol</source><year>1990</year><volume>16</volume><fpage>21</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.3177/jnsv.36.21</pub-id><pub-id pub-id-type="pmid">2163440</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><name><surname>Vaisberg</surname><given-names>MW</given-names></name><name><surname>Kaneno</surname><given-names>R</given-names></name><name><surname>Franco</surname><given-names>MF</given-names></name><name><surname>Mendes</surname><given-names>NF</given-names></name><article-title>Influence of cholecalciferol (vitamin D3) on the course of experimental systemic lupus erythematosus in F1 (NZBxW) mice</article-title><source>J Clin Lab Anal</source><year>2000</year><volume>16</volume><fpage>91</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1098-2825(2000)14:3&#x0003c;91::AID-JCLA2&#x0003e;3.0.CO;2-O</pub-id><pub-id pub-id-type="pmid">10797606</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><name><surname>Kamen</surname><given-names>DL</given-names></name><name><surname>Cooper</surname><given-names>GS</given-names></name><name><surname>Bouali</surname><given-names>H</given-names></name><name><surname>Shaftman</surname><given-names>SR</given-names></name><name><surname>Hollis</surname><given-names>BW</given-names></name><name><surname>Gilkeson</surname><given-names>GS</given-names></name><article-title>Vitamin D deficiency in systemic lupus erythematosus</article-title><source>Autoimmun Rev</source><year>2006</year><volume>16</volume><fpage>114</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1016/j.autrev.2005.05.009</pub-id><pub-id pub-id-type="pmid">16431339</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><name><surname>Borba</surname><given-names>VZ</given-names></name><name><surname>Vieira</surname><given-names>JG</given-names></name><name><surname>Kasamatsu</surname><given-names>T</given-names></name><name><surname>Radominski</surname><given-names>SC</given-names></name><name><surname>Sato</surname><given-names>EI</given-names></name><name><surname>Lazaretti-Castro</surname><given-names>M</given-names></name><article-title>Vitamin D deficiency in patients with active systemic lupus erythematosus</article-title><source>Osteoporos Int</source><year>2009</year><volume>16</volume><fpage>427</fpage><lpage>433</lpage><pub-id pub-id-type="doi">10.1007/s00198-008-0676-1</pub-id><pub-id pub-id-type="pmid">18600287</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><name><surname>Hamza</surname><given-names>RT</given-names></name><name><surname>Awwad</surname><given-names>KS</given-names></name><name><surname>Ali</surname><given-names>MK</given-names></name><name><surname>Hamed</surname><given-names>AI</given-names></name><article-title>Reduced serum concentrations of 25-hydroxy vitamin D in Egyptian patients with systemic lupus erythematosus: relation to disease activity</article-title><source>Med Sci Monit</source><year>2011</year><volume>16</volume><fpage>CR711</fpage><lpage>CR718</lpage><pub-id pub-id-type="pmid">22129903</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><name><surname>Vacca</surname><given-names>A</given-names></name><name><surname>Cormier</surname><given-names>C</given-names></name><name><surname>Piras</surname><given-names>M</given-names></name><name><surname>Mathieu</surname><given-names>A</given-names></name><name><surname>Kahan</surname><given-names>A</given-names></name><name><surname>Allanore</surname><given-names>Y</given-names></name><article-title>Vitamin D deficiency and insufficiency in 2 independent cohorts of patients with systemic sclerosis</article-title><source>J Rheumatol</source><year>2009</year><volume>16</volume><fpage>1924</fpage><lpage>1929</lpage><pub-id pub-id-type="doi">10.3899/jrheum.081287</pub-id><pub-id pub-id-type="pmid">19648299</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><name><surname>Holick</surname><given-names>MF</given-names></name><article-title>Vitamin D deficiency</article-title><source>N Engl J Med</source><year>2007</year><volume>16</volume><fpage>266</fpage><lpage>281</lpage><pub-id pub-id-type="doi">10.1056/NEJMra070553</pub-id><pub-id pub-id-type="pmid">17634462</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><name><surname>Hewison</surname><given-names>M</given-names></name><name><surname>Zehnder</surname><given-names>D</given-names></name><name><surname>Bland</surname><given-names>R</given-names></name><name><surname>Stewart</surname><given-names>PM</given-names></name><article-title>1alpha-hydroxylase and the action of vitamin D</article-title><source>J Mol Endocrinol</source><year>2000</year><volume>16</volume><fpage>141</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1677/jme.0.0250141</pub-id><pub-id pub-id-type="pmid">11013342</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><name><surname>Malaviya</surname><given-names>AN</given-names></name><name><surname>Singh</surname><given-names>RR</given-names></name><name><surname>Singh</surname><given-names>YN</given-names></name><name><surname>Kapoor</surname><given-names>SK</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name><article-title>Prevalence of systemic lupus erythematosus in India</article-title><source>Lupus</source><year>1993</year><volume>16</volume><fpage>115</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1177/096120339300200209</pub-id><pub-id pub-id-type="pmid">8330032</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><name><surname>Kumar</surname><given-names>A</given-names></name><name><surname>Malaviya</surname><given-names>AN</given-names></name><name><surname>Singh</surname><given-names>RR</given-names></name><name><surname>Singh</surname><given-names>YN</given-names></name><name><surname>Adya</surname><given-names>CM</given-names></name><name><surname>Kakkar</surname><given-names>R</given-names></name><article-title>Survival in patients with systemic lupus erythematosus in India</article-title><source>Rheumatol Int</source><year>1992</year><volume>16</volume><fpage>107</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1007/BF00290264</pub-id><pub-id pub-id-type="pmid">1411089</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><name><surname>Murali</surname><given-names>R</given-names></name><name><surname>Jeyaseelan</surname><given-names>L</given-names></name><name><surname>Rajaratnam</surname><given-names>S</given-names></name><name><surname>John</surname><given-names>L</given-names></name><name><surname>Ganesh</surname><given-names>A</given-names></name><article-title>Systemic lupus erythematosus in Indian patients: prognosis, survival and life expectancy</article-title><source>Natl Med J India</source><year>1997</year><volume>16</volume><fpage>159</fpage><lpage>164</lpage><pub-id pub-id-type="pmid">9325637</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><name><surname>Vijay</surname><given-names>J</given-names></name><name><surname>Kapil</surname><given-names>U</given-names></name><article-title>Vitamin d deficiency and its health consequences - a review</article-title><source>Indian J. Community Health</source><year>2012</year><volume>16</volume><fpage>232</fpage><lpage>236</lpage></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><name><surname>Panda</surname><given-names>AK</given-names></name><name><surname>Parida</surname><given-names>JR</given-names></name><name><surname>Tripathy</surname><given-names>R</given-names></name><name><surname>Pattanaik</surname><given-names>SS</given-names></name><name><surname>Ravindran</surname><given-names>B</given-names></name><name><surname>Das</surname><given-names>BK</given-names></name><article-title>Low producer MBL genotypes are associated with susceptibility to systemic lupus erythematosus in Odisha, India</article-title><source>Hum Immunol</source><year>2013</year><volume>16</volume><fpage>114</fpage><lpage>119</lpage><pub-id pub-id-type="pmid">23000377</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><name><surname>Panda</surname><given-names>AK</given-names></name><name><surname>Parida</surname><given-names>JR</given-names></name><name><surname>Tripathy</surname><given-names>R</given-names></name><name><surname>Pattanaik</surname><given-names>SS</given-names></name><name><surname>Ravindran</surname><given-names>B</given-names></name><name><surname>Das</surname><given-names>BK</given-names></name><article-title>Mannose binding lectin: a biomarker of systemic lupus erythematosus disease activity</article-title><source>Arthritis Res Ther</source><year>2012</year><volume>16</volume><fpage>R218</fpage><pub-id pub-id-type="doi">10.1186/ar4057</pub-id><pub-id pub-id-type="pmid">23068019</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><name><surname>Panda</surname><given-names>AK</given-names></name><name><surname>Pattanaik</surname><given-names>SS</given-names></name><name><surname>Tripathy</surname><given-names>R</given-names></name><name><surname>Das</surname><given-names>BK</given-names></name><article-title>TLR-9 promoter polymorphisms (T-1237C and T-1486C) are not associated with systemic lupus erythematosus: A case control study and meta-analysis</article-title><source>Hum Immunol</source><year>2013</year><volume>16</volume><fpage>1672</fpage><lpage>1678</lpage><pub-id pub-id-type="doi">10.1016/j.humimm.2013.08.006</pub-id><pub-id pub-id-type="pmid">23974051</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><name><surname>Hochberg</surname><given-names>MC</given-names></name><article-title>Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus</article-title><source>Arthritis Rheum</source><year>1997</year><volume>16</volume><fpage>1725</fpage><pub-id pub-id-type="pmid">9324032</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><name><surname>Danchenko</surname><given-names>N</given-names></name><name><surname>Satia</surname><given-names>JA</given-names></name><name><surname>Anthony</surname><given-names>MS</given-names></name><article-title>Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden</article-title><source>Lupus</source><year>2006</year><volume>16</volume><fpage>308</fpage><lpage>318</lpage><pub-id pub-id-type="doi">10.1191/0961203306lu2305xx</pub-id><pub-id pub-id-type="pmid">16761508</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><name><surname>Palmer</surname><given-names>P</given-names></name><name><surname>Tovey</surname><given-names>MG</given-names></name><name><surname>Raschilas</surname><given-names>F</given-names></name><name><surname>Brassart</surname><given-names>L</given-names></name><name><surname>Meritet</surname><given-names>JF</given-names></name><name><surname>Porcher</surname><given-names>R</given-names></name><name><surname>Lebon</surname><given-names>P</given-names></name><article-title>Type I interferon subtypes produced by human peripheral mononuclear cells from one normal donor stimulated by viral and non-viral inducing factors</article-title><source>Eur Cytokine Netw</source><year>2007</year><volume>16</volume><fpage>108</fpage><lpage>114</lpage><pub-id pub-id-type="pmid">17594944</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><name><surname>Livak</surname><given-names>KJ</given-names></name><name><surname>Schmittgen</surname><given-names>TD</given-names></name><article-title>Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method</article-title><source>Methods</source><year>2001</year><volume>16</volume><fpage>402</fpage><lpage>408</lpage><pub-id pub-id-type="doi">10.1006/meth.2001.1262</pub-id><pub-id pub-id-type="pmid">11846609</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><name><surname>Ronnblom</surname><given-names>L</given-names></name><article-title>Potential role of IFN alpha in adult lupus</article-title><source>Arthritis Res Ther</source><year>2010</year><volume>16</volume><fpage>S3</fpage><pub-id pub-id-type="doi">10.1186/ar2884</pub-id><pub-id pub-id-type="pmid">20392290</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><name><surname>Niewold</surname><given-names>TB</given-names></name><name><surname>Clark</surname><given-names>DN</given-names></name><name><surname>Salloum</surname><given-names>R</given-names></name><name><surname>Poole</surname><given-names>BD</given-names></name><article-title>Interferon alpha in systemic lupus erythematosus</article-title><source>J Biomed Biotechnol</source><year>2010</year><volume>16</volume><fpage>948364</fpage><pub-id pub-id-type="pmid">20652065</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><name><surname>Bikle</surname><given-names>DD</given-names></name><article-title>Vitamin D and immune function: understanding common pathways</article-title><source>Curr Osteoporos Rep</source><year>2009</year><volume>16</volume><fpage>58</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1007/s11914-009-0011-6</pub-id><pub-id pub-id-type="pmid">19631030</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><name><surname>Cutolo</surname><given-names>M</given-names></name><name><surname>Otsa</surname><given-names>K</given-names></name><article-title>Review: vitamin D, immunity and lupus</article-title><source>Lupus</source><year>2008</year><volume>16</volume><fpage>6</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1177/0961203307085879</pub-id><pub-id pub-id-type="pmid">18089676</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><name><surname>Clemens</surname><given-names>TL</given-names></name><name><surname>Adams</surname><given-names>JS</given-names></name><name><surname>Henderson</surname><given-names>SL</given-names></name><name><surname>Holick</surname><given-names>MF</given-names></name><article-title>Increased skin pigment reduces the capacity of skin to synthesise vitamin D3</article-title><source>Lancet</source><year>1982</year><volume>16</volume><fpage>74</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">6119494</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><name><surname>Ruiz-Irastorza</surname><given-names>G</given-names></name><name><surname>Egurbide</surname><given-names>MV</given-names></name><name><surname>Olivares</surname><given-names>N</given-names></name><name><surname>Martinez-Berriotxoa</surname><given-names>A</given-names></name><name><surname>Aguirre</surname><given-names>C</given-names></name><article-title>Vitamin D deficiency in systemic lupus erythematosus: prevalence, predictors and clinical consequences</article-title><source>Rheumatology (Oxford)</source><year>2008</year><volume>16</volume><fpage>920</fpage><lpage>923</lpage><pub-id pub-id-type="doi">10.1093/rheumatology/ken121</pub-id><pub-id pub-id-type="pmid">18411213</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><name><surname>Muller</surname><given-names>K</given-names></name><name><surname>Kriegbaum</surname><given-names>NJ</given-names></name><name><surname>Baslund</surname><given-names>B</given-names></name><name><surname>Sorensen</surname><given-names>OH</given-names></name><name><surname>Thymann</surname><given-names>M</given-names></name><name><surname>Bentzen</surname><given-names>K</given-names></name><article-title>Vitamin D3 metabolism in patients with rheumatic diseases: low serum levels of 25-hydroxyvitamin D3 in patients with systemic lupus erythematosus</article-title><source>Clin Rheumatol</source><year>1995</year><volume>16</volume><fpage>397</fpage><lpage>400</lpage><pub-id pub-id-type="doi">10.1007/BF02207671</pub-id><pub-id pub-id-type="pmid">7586974</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><name><surname>Chen</surname><given-names>TC</given-names></name><name><surname>Chimeh</surname><given-names>F</given-names></name><name><surname>Lu</surname><given-names>Z</given-names></name><name><surname>Mathieu</surname><given-names>J</given-names></name><name><surname>Person</surname><given-names>KS</given-names></name><name><surname>Zhang</surname><given-names>A</given-names></name><name><surname>Kohn</surname><given-names>N</given-names></name><name><surname>Martinello</surname><given-names>S</given-names></name><name><surname>Berkowitz</surname><given-names>R</given-names></name><name><surname>Holick</surname><given-names>MF</given-names></name><article-title>Factors that influence the cutaneous synthesis and dietary sources of vitamin D</article-title><source>Arch Biochem Biophys</source><year>2007</year><volume>16</volume><fpage>213</fpage><lpage>217</lpage><pub-id pub-id-type="doi">10.1016/j.abb.2006.12.017</pub-id><pub-id pub-id-type="pmid">17254541</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><name><surname>Toloza</surname><given-names>SM</given-names></name><name><surname>Cole</surname><given-names>DE</given-names></name><name><surname>Gladman</surname><given-names>DD</given-names></name><name><surname>Ibanez</surname><given-names>D</given-names></name><name><surname>Urowitz</surname><given-names>MB</given-names></name><article-title>Vitamin D insufficiency in a large female SLE cohort</article-title><source>Lupus</source><year>2010</year><volume>16</volume><fpage>13</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1177/0961203309345775</pub-id><pub-id pub-id-type="pmid">19897520</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><name><surname>Terrier</surname><given-names>B</given-names></name><name><surname>Derian</surname><given-names>N</given-names></name><name><surname>Schoindre</surname><given-names>Y</given-names></name><name><surname>Chaara</surname><given-names>W</given-names></name><name><surname>Geri</surname><given-names>G</given-names></name><name><surname>Zahr</surname><given-names>N</given-names></name><name><surname>Mariampillai</surname><given-names>K</given-names></name><name><surname>Rosenzwajg</surname><given-names>M</given-names></name><name><surname>Carpentier</surname><given-names>W</given-names></name><name><surname>Musset</surname><given-names>L</given-names></name><name><surname>Piette</surname><given-names>JC</given-names></name><name><surname>Six</surname><given-names>A</given-names></name><name><surname>Klatzmann</surname><given-names>D</given-names></name><name><surname>Saadoun</surname><given-names>D</given-names></name><name><surname>Patrice</surname><given-names>C</given-names></name><name><surname>Costedoat-Chalumeau</surname><given-names>N</given-names></name><article-title>Restoration of regulatory and effector T cell balance and B cell homeostasis in systemic lupus erythematosus patients through vitamin D supplementation</article-title><source>Arthritis Res Ther</source><year>2012</year><volume>16</volume><fpage>R221</fpage><pub-id pub-id-type="doi">10.1186/ar4060</pub-id><pub-id pub-id-type="pmid">23075451</pub-id></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal"><name><surname>Ritterhouse</surname><given-names>LL</given-names></name><name><surname>Crowe</surname><given-names>SR</given-names></name><name><surname>Niewold</surname><given-names>TB</given-names></name><name><surname>Kamen</surname><given-names>DL</given-names></name><name><surname>Macwana</surname><given-names>SR</given-names></name><name><surname>Roberts</surname><given-names>VC</given-names></name><name><surname>Dedeke</surname><given-names>AB</given-names></name><name><surname>Harley</surname><given-names>JB</given-names></name><name><surname>Scofield</surname><given-names>RH</given-names></name><name><surname>Guthridge</surname><given-names>JM</given-names></name><name><surname>James</surname><given-names>JA</given-names></name><article-title>Vitamin D deficiency is associated with an increased autoimmune response in healthy individuals and in patients with systemic lupus erythematosus</article-title><source>Ann Rheum Dis</source><year>2011</year><volume>16</volume><fpage>1569</fpage><lpage>1574</lpage><pub-id pub-id-type="pmid">21586442</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal"><name><surname>Cantorna</surname><given-names>MT</given-names></name><name><surname>Mahon</surname><given-names>BD</given-names></name><article-title>Mounting evidence for vitamin D as an environmental factor affecting autoimmune disease prevalence</article-title><source>Exp Biol Med (Maywood)</source><year>2004</year><volume>16</volume><fpage>1136</fpage><lpage>1142</lpage><pub-id pub-id-type="pmid">15564440</pub-id></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal"><name><surname>Chambers</surname><given-names>ES</given-names></name><name><surname>Hawrylowicz</surname><given-names>CM</given-names></name><article-title>The impact of vitamin D on regulatory T cells</article-title><source>Curr Allergy Asthma Rep</source><year>2011</year><volume>16</volume><fpage>29</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1007/s11882-010-0161-8</pub-id><pub-id pub-id-type="pmid">21104171</pub-id></mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal"><name><surname>Kirou</surname><given-names>KA</given-names></name><name><surname>Lee</surname><given-names>C</given-names></name><name><surname>George</surname><given-names>S</given-names></name><name><surname>Louca</surname><given-names>K</given-names></name><name><surname>Peterson</surname><given-names>MG</given-names></name><name><surname>Crow</surname><given-names>MK</given-names></name><article-title>Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease</article-title><source>Arthritis Rheum</source><year>2005</year><volume>16</volume><fpage>1491</fpage><lpage>1503</lpage><pub-id pub-id-type="doi">10.1002/art.21031</pub-id><pub-id pub-id-type="pmid">15880830</pub-id></mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal"><name><surname>Dall&#x02019;era</surname><given-names>MC</given-names></name><name><surname>Cardarelli</surname><given-names>PM</given-names></name><name><surname>Preston</surname><given-names>BT</given-names></name><name><surname>Witte</surname><given-names>A</given-names></name><name><surname>Davis</surname><given-names>JC</given-names><suffix>Jr</suffix></name><article-title>Type I interferon correlates with serological and clinical manifestations of SLE</article-title><source>Ann Rheum Dis</source><year>2005</year><volume>16</volume><fpage>1692</fpage><lpage>1697</lpage><pub-id pub-id-type="pmid">15843451</pub-id></mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal"><name><surname>Feng</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Grossman</surname><given-names>JM</given-names></name><name><surname>Hanvivadhanakul</surname><given-names>P</given-names></name><name><surname>FitzGerald</surname><given-names>JD</given-names></name><name><surname>Park</surname><given-names>GS</given-names></name><name><surname>Dong</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Kim</surname><given-names>MH</given-names></name><name><surname>Weng</surname><given-names>HH</given-names></name><name><surname>Furst</surname><given-names>DE</given-names></name><name><surname>Gorn</surname><given-names>A</given-names></name><name><surname>McMahon</surname><given-names>M</given-names></name><name><surname>Taylor</surname><given-names>M</given-names></name><name><surname>Brahn</surname><given-names>E</given-names></name><name><surname>Hahn</surname><given-names>BH</given-names></name><name><surname>Tsao</surname><given-names>BP</given-names></name><article-title>Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus</article-title><source>Arthritis Rheum</source><year>2006</year><volume>16</volume><fpage>2951</fpage><lpage>2962</lpage><pub-id pub-id-type="doi">10.1002/art.22044</pub-id><pub-id pub-id-type="pmid">16947629</pub-id></mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal"><name><surname>Bennett</surname><given-names>L</given-names></name><name><surname>Palucka</surname><given-names>AK</given-names></name><name><surname>Arce</surname><given-names>E</given-names></name><name><surname>Cantrell</surname><given-names>V</given-names></name><name><surname>Borvak</surname><given-names>J</given-names></name><name><surname>Banchereau</surname><given-names>J</given-names></name><name><surname>Pascual</surname><given-names>V</given-names></name><article-title>Interferon and granulopoiesis signatures in systemic lupus erythematosus blood</article-title><source>J Exp Med</source><year>2003</year><volume>16</volume><fpage>711</fpage><lpage>723</lpage><pub-id pub-id-type="doi">10.1084/jem.20021553</pub-id><pub-id pub-id-type="pmid">12642603</pub-id></mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal"><name><surname>Reichel</surname><given-names>H</given-names></name><name><surname>Koeffler</surname><given-names>HP</given-names></name><name><surname>Tobler</surname><given-names>A</given-names></name><name><surname>Norman</surname><given-names>AW</given-names></name><article-title>1 alpha,25-dihydroxyvitamin D3 inhibits gamma-interferon synthesis by normal human peripheral blood lymphocytes</article-title><source>Proc Natl Acad Sci U S A</source><year>1987</year><volume>16</volume><fpage>3385</fpage><lpage>3389</lpage><pub-id pub-id-type="doi">10.1073/pnas.84.10.3385</pub-id><pub-id pub-id-type="pmid">3033646</pub-id></mixed-citation></ref><ref id="B49"><mixed-citation publication-type="journal"><name><surname>Griffin</surname><given-names>MD</given-names></name><name><surname>Lutz</surname><given-names>WH</given-names></name><name><surname>Phan</surname><given-names>VA</given-names></name><name><surname>Bachman</surname><given-names>LA</given-names></name><name><surname>McKean</surname><given-names>DJ</given-names></name><name><surname>Kumar</surname><given-names>R</given-names></name><article-title>Potent inhibition of dendritic cell differentiation and maturation by vitamin D analogs</article-title><source>Biochem Biophys Res Commun</source><year>2000</year><volume>16</volume><fpage>701</fpage><lpage>708</lpage><pub-id pub-id-type="doi">10.1006/bbrc.2000.2490</pub-id><pub-id pub-id-type="pmid">10772887</pub-id></mixed-citation></ref></ref-list></back></article>